Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer

Reuters

2025/12/12

Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer

Natera Inc., a global leader in cell-free DNA and precision medicine, has announced a collaboration with MEDSIR, a prominent oncology research organization, for the MiRaDoR phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The study will use Natera's Signatera Genome technology to evaluate the effectiveness of different therapeutic approaches in early-stage HR+/HER2- breast cancer patients. The trial aims to assess the ability of various treatment combinations to reduce circulating-tumor DNA as a marker of treatment response, potentially setting a new standard for precision oncology clinical trials. The collaboration is supported by funding from F. Hoffman-La Roche Ltd. and is currently enrolling patients across several sites, with further expansions planned in Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212609556) on December 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590096185"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590096185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590096185?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590096185","market":"us","top_or_hot":-1,"title":"Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Natera Inc., a global leader in cell-free DNA and precision medicine, has announced a collaboration with MEDSIR, a prominent oncology research organization, for the MiRaDoR phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The study will use Natera's Signatera Genome technology to evaluate the effectiveness of different therapeutic approaches in early-stage HR+/HER2- breast cancer patients. The trial aims to assess the ability of various treatment combinations to reduce circulating-tumor DNA as a marker of treatment response, potentially setting a new standard for precision oncology clinical trials. The collaboration is supported by funding from F. Hoffman-La Roche Ltd. and is currently enrolling patients across several sites, with further expansions planned in Europe.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212609556) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-12 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Natera Inc., a global leader in cell-free DNA and precision medicine, has announced a collaboration with MEDSIR, a prominent oncology research organization, for the MiRaDoR phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The study will use Natera's Signatera Genome technology to evaluate the effectiveness of different therapeutic approaches in early-stage HR+/HER2- breast cancer patients. The trial aims to assess the ability of various treatment combinations to reduce circulating-tumor DNA as a marker of treatment response, potentially setting a new standard for precision oncology clinical trials. The collaboration is supported by funding from F. Hoffman-La Roche Ltd. and is currently enrolling patients across several sites, with further expansions planned in Europe.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212609556) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1988902786.USD","symbol_name":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL10sNlk:1","article_id":"2590096185","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590096185","pubTimestamp":1765544463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Natera Inc., a global leader in cell-free DNA and precision medicine, has announced a collaboration with MEDSIR, a prominent oncology research organization, for the MiRaDoR phase II clinical trial in hormone receptor-positive, HER2-negative  breast cancer. The study will use Natera's Signatera Genome technology to evaluate the effectiveness of different therapeutic approaches in early-stage HR+/HER2- breast cancer patients. The trial aims to assess the ability of various treatment combinations to reduce circulating-tumor DNA as a marker of treatment response, potentially setting a new standard for precision oncology clinical trials. The collaboration is supported by funding from F. Hoffman-La Roche Ltd. and is currently enrolling patients across several sites, with further expansions planned in Europe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","NTRA":"Natera, Inc.","BK4139":"生物科技","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD"},"translate_title":"Natera和MEDSIR在HR+/HER2-乳腺癌中启动MiRaDoR试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":0.9},"content_text":"Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer\n    \n\n        Natera Inc., a global leader in cell-free DNA and precision medicine, has announced a collaboration with MEDSIR, a prominent oncology research organization, for the MiRaDoR phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The study will use Natera's Signatera Genome technology to evaluate the effectiveness of different therapeutic approaches in early-stage HR+/HER2- breast cancer patients. The trial aims to assess the ability of various treatment combinations to reduce circulating-tumor DNA as a marker of treatment response, potentially setting a new standard for precision oncology clinical trials. The collaboration is supported by funding from F. Hoffman-La Roche Ltd. and is currently enrolling patients across several sites, with further expansions planned in Europe.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251212609556) on December 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}